Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below 200-Day Moving Average – Here’s Why

Atossa Genetics Inc. (NASDAQ:ATOS) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $7.14 and traded as low as $4.65. Atossa Genetics shares last traded at $4.85, with a volume of 46,768 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ATOS. Weiss Ratings raised Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. HC Wainwright upped their price target on shares of Atossa Genetics to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Finally, Ascendiant Capital Markets lowered their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $24.50.

Atossa Genetics Trading Up 3.2%

The company’s 50-day moving average is $5.24 and its 200-day moving average is $7.14. The firm has a market cap of $41.76 million, a price-to-earnings ratio of -1.51 and a beta of 1.24.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Friday, May 8th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.12). Equities research analysts forecast that Atossa Genetics Inc. will post -4.41 EPS for the current year.

Institutional Trading of Atossa Genetics

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in Atossa Genetics by 51.3% in the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after buying an additional 37,809 shares in the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Atossa Genetics in the second quarter worth about $381,000. Ameriprise Financial Inc. acquired a new stake in shares of Atossa Genetics in the 2nd quarter valued at approximately $2,468,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Atossa Genetics in the 2nd quarter valued at approximately $26,000. 12.74% of the stock is currently owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.